PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock
62.83 USD
+0.41 (+0.66%)
62.83 USD
0 (0%)
Overall PBH gets a fundamental rating of 6 out of 10. We evaluated PBH against 192 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making PBH a very profitable company, without any liquidiy or solvency issues. PBH is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
PBH had a positive operating cash flow in the past year.
PBH had positive earnings in 4 of the past 5 years.
Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.83%, PBH belongs to the top of the industry, outperforming 86.98% of the companies in the same industry.
Looking at the Return On Equity, with a value of 11.00%, PBH belongs to the top of the industry, outperforming 85.94% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 7.88%, PBH belongs to the top of the industry, outperforming 85.94% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for PBH is below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROIC | 7.88% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
PBH has a Profit Margin of 18.09%. This is amongst the best in the industry. PBH outperforms 90.10% of its industry peers.
PBH's Profit Margin has improved in the last couple of years.
PBH has a better Operating Margin (31.00%) than 94.27% of its industry peers.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
PBH has a better Gross Margin (56.10%) than 67.19% of its industry peers.
In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PBH is destroying value.
The number of shares outstanding for PBH has been reduced compared to 1 year ago.
PBH has less shares outstanding than it did 5 years ago.
The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
PBH has an Altman-Z score of 2.56. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
PBH has a better Altman-Z score (2.56) than 61.98% of its industry peers.
The Debt to FCF ratio of PBH is 3.97, which is a good value as it means it would take PBH, 3.97 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.97, PBH belongs to the top of the industry, outperforming 85.94% of the companies in the same industry.
A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
PBH has a Debt to Equity ratio of 0.55. This is in the lower half of the industry: PBH underperforms 66.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 2.56 |
ROIC/WACC0.89
WACC8.84%
2.3 Liquidity
A Current Ratio of 3.70 indicates that PBH has no problem at all paying its short term obligations.
PBH has a Current ratio (3.70) which is comparable to the rest of the industry.
PBH has a Quick Ratio of 2.51. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
PBH's Quick ratio of 2.51 is in line compared to the rest of the industry. PBH outperforms 51.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.15% over the past year.
PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
The Revenue has decreased by -0.02% in the past year.
PBH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.39% yearly.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
PBH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.13% yearly.
Based on estimates for the next years, PBH will show a small growth in Revenue. The Revenue will grow by 1.15% on average per year.
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.78, the valuation of PBH can be described as correct.
Based on the Price/Earnings ratio, PBH is valued cheaply inside the industry as 88.02% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.59. PBH is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 12.83, the valuation of PBH can be described as correct.
84.38% of the companies in the same industry are more expensive than PBH, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 24.03. PBH is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.78 | ||
| Fwd PE | 12.83 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaply inside the industry as 86.98% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PBH is valued cheaper than 89.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.83 | ||
| EV/EBITDA | 10.43 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)8.4
PEG (5Y)1.55
EPS Next 2Y3.96%
EPS Next 3Y3.41%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
62.83
+0.41 (+0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners108.93%
Inst Owner Change-0.57%
Ins Owners1.31%
Ins Owner Change0.82%
Market Cap3.02B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Analysts84
Price TargetN/A
Short Float %3.77%
Short Ratio4.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)-4.08%
PT rev (3m)-7.3%
EPS NQ rev (1m)0.04%
EPS NQ rev (3m)-9.36%
EPS NY rev (1m)0.96%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)0.06%
Revenue NQ rev (3m)-5.22%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)0.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.78 | ||
| Fwd PE | 12.83 | ||
| P/S | 2.72 | ||
| P/FCF | 11.83 | ||
| P/OCF | 11.47 | ||
| P/B | 1.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.43 |
EPS(TTM)4.56
EY7.26%
EPS(NY)4.9
Fwd EY7.79%
FCF(TTM)5.31
FCFY8.46%
OCF(TTM)5.48
OCFY8.72%
SpS23.1
BVpS37.96
TBVpS-20.68
PEG (NY)8.4
PEG (5Y)1.55
Graham Number62.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROCE | 10.41% | ||
| ROIC | 7.88% | ||
| ROICexc | 8.17% | ||
| ROICexgc | 70.59% | ||
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% | ||
| FCFM | 23% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 27.11% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.8 | ||
| Cash Conversion | 70.49% | ||
| Profit Quality | 127.19% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | 2.56 |
F-Score7
WACC8.84%
ROIC/WACC0.89
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y3.05%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
What is the valuation status for PBH stock?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
How profitable is PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
How financially healthy is PRESTIGE CONSUMER HEALTHCARE?
The financial health rating of PRESTIGE CONSUMER HEALTHCARE (PBH) is 7 / 10.
What is the earnings growth outlook for PRESTIGE CONSUMER HEALTHCARE?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.64% in the next year.